vaccine_addendum_4.pdf
PDF 137 KB Posted
- Attached to
- MMCAP Infuse Notice of RFP 34056 - Distribution of Vaccines and Vaccine-related Products
- Solicitation number
- S-10700-00014515
- Issued by
- Oregon
About this file
This is Addendum No. 4 to the Request for Proposals issued by MMCAP Infuse (the Multi-State Cooperative Agreement Program operating through the Minnesota Department of Administration) for the distribution of vaccines and vaccine-related products. The addendum, dated May 7, 2024, addresses sixteen clarifying questions submitted by prospective responders regarding various aspects of the RFP and draft agreement template. Key clarifications include confirmation that existing customer accounts may be used for vaccine orders subject to negotiation with awarded responders, that separate Master Participation Addendums (MPAs) are required for each specific MMCAP Infuse agreement, and that MMCAP Infuse reserves the right to award the solicitation to either a single responder or multiple responders. The initial contract term is established at two years with an option to extend for three additional one-year periods upon mutual agreement of the parties. The response deadline for the RFP was May 21, 2024, at 2:00 p.m. Central Time. Responders must demonstrate relationships with at least ten of the listed suppliers identified in Exhibit F of the RFP, and all minimum qualifications and compliance responsibilities remain with the responder, including those of any affiliated entities handling physical distribution.
The addendum clarifies several administrative and operational requirements for awarded responders, including that sales reporting will be negotiated and determined based on member-specific needs, pricing negotiations on the 3% administrative fee are possible for each category (flu and vaccine offerings), and monthly Raw and Adjusted Fill Rate Reports are required. Member-requested participation fees and federal funding notifications will be handled through individual MPAs and direct member communication with responders, respectively. The addendum emphasizes that all redlined terms of the draft Agreement Template (Exhibit B) will be subject to negotiation following the evaluation phase, with responders notified by email at mmcap_infuse.rfp@state.mn.us. Product dating verification and dispute resolution procedures will be determined based on individual member requirements and procedures. Responders must provide comprehensive information regarding their capabilities, affiliations, and compliance attestations, as the RFP submission constitutes a binding offer requiring responder authority and accuracy of all submitted information.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| vaccine_addendum_2.pdf | ||
| word_doc_for_section_3_exhibits_fgk.docx | DOCX document | |
| vaccine_addendum_3.pdf | ||
| agreement_template_final.docx | DOCX document | |
| vaccine_addendum_1.pdf | ||
| Notice of Intent to Award_S-1070-0014489 DPSST Bldg F Structural Upgrades.docx | DOCX document | |
| data_non_flu_vaccines_and_related_product.ods | ODS spreadsheet | |
| vaccine_rfp_final~1.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
MMCAP Infuse
Request for Proposals (RFP) Addendum
Addendum # 4
Addendum No.: 4 Date of Addendum: May 7, 2024
Due Date, Time: May 21, 2024, at Revised Date, Time: N/A 2:00pm Central Time
MMCAP Infuse Department of Administration/OSP/
RFP Coordinator: Nalee Xiong Agency: MMCAP Infuse
OSP Website Reference No.: 34056
RFP Title: Distribution of Vaccines and Vaccine-related Products
Scope of Addendum
The following are answers to questions submitted to MMCAP Infuse:
1. Question: We would use current accounts when customers order Flu vaccine and other vaccines from distributor. Is MMCAP expecting distributor to create separate “Vaccine” accounts for existing customers?
Answer: For awarded Responders, this would be subject to the negotiations.
2. Question: Certain items on the spreadsheet are covered under the current (and future) MMCAP distributor/wholesaler agreement. Are those items able to remain under the wholesaler agreement, and distributor contracts separately for flu and covid vaccines?
Answer: For awarded Responders, this would be subject to the negotiations.
3. Question: For states that currently have an MPA, will a separate MPA be needed for the MMCAP
RFP/Wholesaler and the Vaccine contracts?
Answer: Yes, MPAs (Member-requested Participation Addendums) are tied to a specific MMCAP Infuse agreement.
4. Question: Will distributor need to send separate sales reports for the vaccine sales data and the normal MMCAP distributor/wholesaler contract sales?
Answer: For awarded Responders, this will be subject to the negotiations. Sales reporting is required of MMCAP Infuse contracted vendors.
5. Question: In years past, MMCAP has offered three, one-year extensions by mutual consent upon expiration. Will this be the same for the resulting contract?
Answer: MMCAP Infuse intends to issue contracts for an initial term of two years with an option to extend an additional three, one-year periods, upon mutual agreement of the parties.
6. Question: Historically, MMCAP has awarded multiple Vendors. Will MMCAP award multiple Vendors in response to this RFP? If so, is there a designated number of Vendors that MMCAP plans to award?
Answer: MMCAP Infuse reserves the right to award this solicitation to a single Responder, or to multiple Responders, and the State of Minnesota reserves the right to cancel this solicitation if it is considered in its best interest.
7. Question: Statement number three on page six (6) requires that Responders have a relationship with at least ten of the listed suppliers in Exhibit F. The RFP does not contain an Exhibit F, however there is a list of suppliers on Attachment F. Are the suppliers referenced on Attachment F the suppliers with which the Responder must have a relationship? Alternatively, is the RFP missing Exhibit F?
Answer: Exhibit F is located on page 26 of the RFP. Be sure to distinguish between Exhibit F of the RFP and Attachment F of the Agreement Template (Exhibit B).
8. Question: Article I, Paragraph 1.2 states that, "The fees will be set aside and paid to the Member as detailed in a form provided and approved by MMCAP Infuse." Please clarify what is meant by "form."
Answer: A Member Fee would be detailed and accounted for in an MPA (Member-requested Participation Addendum). The form of remitting and reporting the Member Fee would vary based on the needs of the requesting Member and would be outlined in the respective MPA.
9. Question: As per the definition of Administrative Fee in the RFP it appears that the 3% percent
Administrative Fee applies to both the Flu and Vaccine category offerings. Is MMCAP open to negotiation on the final percentages for each category or is it expected to be the same for both categories?
Answer: For awarded Responders, this will be subject to the negotiations.
10. Question: If awarded, will the Responder and MMCAP negotiate the redlined terms of the Agreement
Template in order to execute a final Agreement? If not, how will MMCAP provide notice to Responder regarding the acceptance or rejection of redlined terms?
Answer: All Responders will be notified by email from MMCAP Infuse RFP Inbox (mmcap_infuse.rfp@state.mn.us) once the evaluation phase is complete. MMCAP Infuse expects to receive a redlined Exhibit B: Agreement Template for your proposal to be considered complete. The acceptance and rejection of the redlined terms will be negotiated.
11. Question: Please confirm the nature of the dispute for which the Responder should provide a dispute resolution process.
Answer: Any and all disputes that could arise between the responder and a Member and/or MMCAP Infuse. Examples of what would be considered a dispute can be found in the draft agreement.
12. Question: Article I, Paragraph 1.4 Product Dating of the Agreement Template: How will the responder verify the "date of acceptance" of the Product by the member? Is the member required to notify the Responder in writing?
Answer: This will be dependent upon each Member’s procedures of receiving product.
13. Question: Article II, Paragraph 2.4 of the Agreement Template: How and at what point in the ordering process will the Responder be notified that Federal funds will be used? Who is responsible for providing the notice to the Vendor?
Answer: Members are responsible for notifying awarded Responder(s) of the use of federal funds and any requirements imposed. The notice that a Member provides is to be determined between the Responder and the Member.
14. Question: Attachment A, Paragraph 1F and Attachment D of the Agreement template: Please confirm if the Raw and Adjusted Fill Rate Report is due monthly or quarterly.
Answer: Monthly.
15. Question: Attachment A, Paragraph 2Ai of the Agreement Template: Please confirm which pricing, if any, should be loaded while the discrepancy is being discussed with MMCAP Infuse.
Answer: Vendor will process product adds/deletes/price changes based on documentation received from manufacturers/suppliers and perform weekly audit of previous week changes, notifying MMCAP Infuse of any specific discrepancies in writing to the MMCAP Infuse at (MMCAP_Infuse.Contracts@state.mn.us).
16. Question: Is it acceptable for the Minimum Qualifications Required (Pass/Fail Criteria) to be met by
Responder’s affiliate that would be handling the physical distribution of the flu/vaccine products?
Answer: All responsibility for the RFP and compliance with the terms of the draft agreement and the RFP content lies with the Responder. The submission of a response to this RFP is a binding offer for contract by the Responder, who must have the authority to do so. The submission of an RFP response also requires that the Responder attest that the information within the proposal is true, correct, and reliable for purposes of the evaluation for a potential contract award. This includes information pertaining to the affiliate relationships.
File details come from the government source that posted it. Updated .